Evenity (Romosozumab) Cost in New Jersey: 2026 Pricing, Insurance & Savings

Evenity (romosozumab-aqqg) is an FDA-approved monoclonal antibody, given as a monthly subcutaneous injection, for postmenopausal women with osteoporosis at high risk of fracture. It is not the same drug class as bisphosphonates (alendronate, risedronate) or denosumab, and it is not interchangeable with them in a treatment plan. This article separates what is stable and verifiable about Evenity, its FDA labeling and clinical evidence, from what is date-sensitive and must be reconfirmed at the time a New Jersey patient actually fills a prescription: retail price, specific plan copays, and Medicaid MCO procedures.

Direct answer: Evenity has no generic or biosimilar competitor as of this writing, so its list price is set by the manufacturer and does not vary by pharmacy the way a generic drug's price would. Out-of-pocket cost for a New Jersey patient depends far more on insurance type (commercial, Medicaid, or Medicare), prior-authorization approval, and whether billing runs through the medical benefit or pharmacy benefit than on which pharmacy or county fills the prescription. Manufacturer figures and specific dollar amounts referenced below should be verified directly with the pharmacy, the prescribing office's billing staff, or the patient's insurer before a patient relies on them financially.

What is established versus what needs verification

Established and stable (federal/clinical facts, unlikely to change quickly):

• Evenity (romosozumab-aqqg) received FDA approval in 2019 for osteoporosis treatment in postmenopausal women at high fracture risk, including those who have failed or cannot tolerate other osteoporosis therapies. Current label details should be confirmed directly on the FDA's drug approval database.
• Evenity carries an FDA boxed warning for potential increased risk of myocardial infarction, stroke, and cardiovascular death. It is generally not appropriate for patients who have had a heart attack or stroke within the preceding year, and this warning is why plans typically require cardiovascular risk documentation before approving coverage.
• Treatment duration is limited to 12 monthly doses; romosozumab is not intended for indefinite use because its anabolic (bone-building) effect diminishes over time.
• Two pivotal trials, commonly referenced as ARCH (romosozumab followed by alendronate versus alendronate alone) and FRAME (romosozumab versus placebo), reported reductions in new vertebral fractures in the treatment arms. The exact effect sizes cited in older marketing and educational material should be checked against the original published trials before being used in a clinical or financial decision, since secondary sources sometimes misstate them.
• 503A compounding pharmacies in New Jersey are regulated under state pharmacy board rules and general FDA compounding policy, which restricts compounding to patient-specific prescriptions rather than bulk production. See the FDA's compounding laws and policies page for the federal framework.

Date-sensitive and must be reverified at the time of care (insurer, state, pharmacy, and cash-price facts):

• The manufacturer list price (wholesale acquisition cost) per monthly dose.
• Whether a specific NJ Medicaid managed care organization or commercial plan currently requires step therapy, and what its prior-authorization form and turnaround time look like.
• Whether the manufacturer's copay savings program is active, what its terms are, and whether a patient's specific plan uses a copay accumulator that would blunt its benefit.
• Medicare Part B deductible and coinsurance amounts, which change annually.
• Which specialty pharmacies or 340B-eligible NJ hospital clinics currently stock and bill for Evenity, and their current dispensing arrangements.

What is publicly reported about price (verify before relying on it)

Industry pricing trackers and pharmacy benefit summaries have reported a list price in the range of roughly $1,800 per monthly injection for Evenity, which would put a full 12-dose course in the low tens of thousands of dollars before insurance. These figures are not drawn from a New Jersey-specific, dated primary source in this review and should be confirmed directly with a specialty pharmacy or the prescribing office's billing department, since manufacturer list prices are revised periodically and a patient's actual bill depends heavily on whether the drug is billed under the medical benefit (physician-administered, J-code J3111) or the pharmacy benefit (dispensed for self- or clinic-administration).

Because there is no generic or biosimilar romosozumab on the market as of this writing, brand-name cash price does not vary meaningfully by pharmacy the way it would for an older, genericized drug.

New Jersey Medicaid (NJ FamilyCare) coverage

New Jersey Medicaid covers Evenity with prior authorization when a patient meets criteria consistent with the FDA indication: postmenopausal women at high fracture risk, generally documented by a DXA T-score at or below -2.5, a prior fragility fracture, or failure of or intolerance to another osteoporosis therapy. Each NJ FamilyCare managed care organization (for example, Aetna Better Health, Amerigroup, Horizon NJ Health, Molina, UnitedHealthcare Community Plan, or WellCare) may use its own prior-authorization form and processing timeline, though state Medicaid coverage rules apply once criteria are met. Specific PA turnaround times and appeal windows change and should be confirmed with the plan or the NJ Division of Medical Assistance and Health Services directly rather than assumed from this article.

New Jersey Evenity cost verification checklist

Use this checklist to separate facts a patient or caregiver can trust as stable from facts that must be reconfirmed before making a financial decision.

Stable facts to confirm once, from primary sources:

• Current FDA-approved indication and boxed warning, checked directly with the FDA's drug approval database
• Treatment course length (12 monthly doses) and route of administration
• Whether the patient has a cardiovascular history that may make Evenity inappropriate (recent MI or stroke)
• General 503A compounding rules under FDA and NJ Board of Pharmacy policy, if a compounded product is being considered

Volatile facts to reconfirm at the time of prescribing, ideally in writing:

• Current list price and specialty pharmacy cash price, obtained directly from the dispensing pharmacy
• Whether the patient's specific commercial plan requires bisphosphonate step therapy, and what documentation supports an exception
• Whether the drug will bill under the medical benefit or pharmacy benefit for this specific patient's care setting, and what each pathway would cost
• Current NJ Medicaid MCO prior-authorization form, required documentation, and appeal deadline for the specific plan the patient is enrolled in
• Whether the manufacturer copay savings program is currently active, its exact terms, and whether the patient's plan applies a copay accumulator
• Current Medicare Part B annual deductible and 20% coinsurance amount for the plan year in question
• Whether a 340B-eligible NJ clinic or hospital-affiliated practice is being used, and how that affects billed cost
• Income eligibility thresholds and required documents for manufacturer patient assistance or foundation grant programs, confirmed the same month as application

Commercial insurance and the medical-versus-pharmacy-benefit question

Commercial plans sold or offered through New Jersey employers and the marketplace generally place Evenity on a specialty tier and require prior authorization, and many require documentation of a trial of an oral bisphosphonate first. Whether Evenity is billed under the medical benefit (when given in a physician's office, billed under J-code J3111, with the patient owing coinsurance) or the pharmacy benefit (when dispensed through a specialty pharmacy) can change out-of-pocket cost substantially. Patients should ask their insurer directly which pathway applies to their specific plan and site of care rather than assuming a flat copay.

Manufacturer savings support

Amgen has historically offered a copay assistance program for commercially insured patients prescribed Evenity, which can reduce or eliminate the copay for eligible patients for a defined period. These programs typically exclude patients on Medicare, Medicaid, or other government insurance, and enrollment terms change. A separate patient assistance program has historically existed for income-eligible patients, including some Medicare beneficiaries, providing free medication rather than a copay discount. Because eligibility rules, dollar caps, and enrollment procedures are updated by the manufacturer, patients should confirm current terms directly with the manufacturer's support program before counting on a specific savings amount.

New Jersey has not, as of this writing, enacted legislation banning copay accumulator programs, meaning a savings card's payments may or may not count toward a patient's deductible or out-of-pocket maximum depending on how the specific plan is structured. This is worth asking about before enrolling, since a patient could face a cost cliff once the manufacturer support period ends if accumulator rules applied throughout.

Medicare Part B coverage

Medicare Part B can cover Evenity when it is administered in a physician's office, billed as a Part B drug. Standard Part B cost-sharing after the annual deductible is 20% coinsurance, and the deductible amount itself changes each calendar year, so a specific dollar coinsurance figure from a prior year should not be assumed to apply going forward. A Medigap plan can reduce or eliminate this coinsurance. Medicare Advantage plans set their own prior-authorization criteria for Part B drugs, which vary by plan and by year.

Compounded romosozumab: what patients should understand

Licensed 503A compounding pharmacies in New Jersey are permitted, under state and federal rules, to compound medications for an individual patient with a valid prescription. However, romosozumab is a monoclonal antibody biologic, and monoclonal antibody manufacturing typically requires mammalian cell culture and extensive quality controls that standard compounding pharmacies are not equipped to replicate. A compounded version would not have undergone the FDA's biologic approval process, including the bioequivalence, stability, and batch-release testing that apply to Amgen's branded product. Patients considering a compounded alternative should discuss this quality-assurance gap directly with their prescriber and, if proceeding, request a certificate of analysis and check the pharmacy's inspection history through the NJ Board of Pharmacy's public records. This article is not a recommendation for or against compounded romosozumab; it is a description of the regulatory distinction a patient needs to weigh.

Telehealth prescribing in New Jersey

New Jersey permits establishing a prescriber-patient relationship through synchronous telehealth for osteoporosis management, and state telehealth parity law generally requires insurers to reimburse telehealth visits comparably to in-person visits. A telehealth visit can support the prescribing decision, fracture-risk assessment, and prior-authorization documentation, but the injection itself still requires an in-person encounter at a clinic, infusion center, or through home health services. This can be useful for patients in counties with limited endocrinology or rheumatology access, provided the virtual prescriber coordinates with a local site for administration.

Cardiovascular safety and when this affects the coverage decision

Because of the boxed warning for cardiovascular events, most New Jersey plans require the prescriber to confirm the patient has not had a myocardial infarction or stroke in the past year and, in some cases, to document a formal cardiovascular risk assessment as part of prior authorization. A patient with recent cardiac or cerebrovascular disease should not expect coverage approval and should discuss alternative osteoporosis therapies with their prescriber. Chest pain, sudden weakness, slurred speech, or other stroke or heart attack symptoms during treatment are a reason to seek emergency care immediately, not to wait for a follow-up appointment.

Evidence boundary

What is established: Evenity is FDA-approved for a specific population, carries a boxed cardiovascular warning, and clinical trials have shown fracture-risk reduction compared with placebo and with an active bisphosphonate comparator in the trials' study populations. New Jersey Medicaid and most commercial insurers cover it with prior authorization, generally after bisphosphonate step therapy for commercial plans.

What is plausible but requires verification: specific published effect sizes from the pivotal trials, the exact current list price, and current plan-specific copay amounts. This review could not confirm precise figures against verified primary sources and flags them for confirmation before use in patient counseling.

What is not established from the material reviewed here: any claim about cost-effectiveness expressed as a precise dollars-per-QALY figure, any calculated number-needed-to-treat specific to a hypothetical patient, and any attributed clinical quotation. These have been removed from this draft because they could not be verified against a primary source and should not be reintroduced without a checked citation.